How should apixaban be dosed for a patient with a provoked deep‑vein thrombosis from long‑haul travel, including loading and maintenance doses, dose‑reduction criteria (age ≥ 80 years, weight ≤ 60 kg, impaired renal function), and alternatives if severe renal impairment or contraindications are present?

Apixaban Dosing for Provoked DVT from Long-Haul Travel

For a patient with provoked deep vein thrombosis from long-haul travel, initiate apixaban 10 mg orally twice daily for 7 days, then reduce to 5 mg twice daily for a total of 3 months, with no dose reduction needed for age ≥80 years, weight ≤60 kg, or mild-to-moderate renal impairment. 1, 2, 3

Loading Phase (Days 1-7)

• Start apixaban 10 mg orally twice daily for the first 7 days without any parenteral anticoagulation lead-in 1, 2, 4
• This loading dose provides immediate therapeutic anticoagulation and eliminates the need for bridging with enoxaparin or unfractionated heparin 2, 3
• The AMPLIFY trial demonstrated this regimen was non-inferior to enoxaparin/warfarin with significantly lower major bleeding (0.6% vs 1.8%, P<0.001) 1, 4

Maintenance Phase (Day 8 onwards)

• Transition to apixaban 5 mg orally twice daily starting on day 8 1, 2, 3
• Continue this maintenance dose for a minimum total duration of 3 months for provoked DVT 5, 2
• Long-haul travel is considered a transient/reversible provoking factor, so anticoagulation can be discontinued after 3 months 5

Dose Reduction Criteria: Common Pitfall

Critical point: The criteria you mentioned (age ≥80, weight ≤60 kg) do NOT apply to apixaban for VTE treatment. 2, 3

• These reduction criteria apply to atrial fibrillation dosing only, not VTE treatment 2
• For VTE treatment, use the standard 10 mg twice daily × 7 days, then 5 mg twice daily regardless of age or weight (unless severe renal impairment) 1, 2, 3
• The only exception is for extended therapy beyond 6 months, where 2.5 mg twice daily can be considered, but this does not apply to your patient with provoked DVT requiring only 3 months 5, 2

Renal Function Considerations

• CrCl ≥30 mL/min: Use standard dosing (10 mg twice daily × 7 days, then 5 mg twice daily) with no adjustment needed 2, 3
• CrCl 15-29 mL/min: Apixaban can be used with caution at standard dosing, though data are limited 2
• CrCl <15 mL/min: Apixaban is contraindicated; use enoxaparin 1 mg/kg subcutaneously every 12 hours with anti-Xa monitoring or unfractionated heparin instead 2, 3

Alternative Anticoagulants for Contraindications

If apixaban is contraindicated or unavailable:

• Rivaroxaban: 15 mg orally twice daily with food for 21 days, then 20 mg once daily 1, 6
• Enoxaparin: 1 mg/kg subcutaneously every 12 hours for 3 months (preferred if severe renal impairment CrCl <30 mL/min) 6, 2
• Edoxaban: Requires 5-10 days of parenteral anticoagulation first, then 60 mg once daily (or 30 mg if weight <60 kg or CrCl 30-50 mL/min) 1, 6
• Dabigatran: Requires 5-10 days of parenteral anticoagulation first, then 150 mg twice daily 1, 6

Monitoring Requirements

• No routine laboratory monitoring required for apixaban at standard doses 2, 7
• Baseline labs: CBC with platelets, renal function, hepatic function, PT/INR 6
• Recheck hemoglobin/hematocrit if bleeding suspected, but routine monitoring not needed 6

Duration Decision Algorithm

Since this is provoked DVT from travel (transient risk factor):

1. Stop anticoagulation after 3 months 5, 2
2. Do not extend therapy beyond 3 months unless DVT recurs 5
3. The 2021 CHEST guidelines and 2019 ESC guidelines both recommend discontinuing anticoagulation after 3 months for VTE with major transient/reversible risk factors 5